ExpreS2ion Biotechnologies: Enters term sheet on commercialization of malaria vaccines

ExpreS2ion Biotechnologies announced yesterday that the company has signed a term sheet with Serum Institute of India Private Limited (SIIPL), a leading global vaccine manufacturer. Upon execution of a definitive agreement, SIIPL will obtain rights to develop, manufacture, and commercialize the malaria vaccines currently in Phase I and Phase II together with the University of Oxford. 

ExpreS2ion Biotechnologies disclosed that they will receive limited undisclosed development and regulatory milestone payments, if successful and launched, lower single-digit percentage royalties based on future net sales of these products.

This follows the update in the journal, The Lancet, that highlighted the clinical progress of the lead malaria vaccine candidate. The promising findings reported by the University of Oxford further validate the potential of these vaccine candidates for combatting malaria.

There is no information about whether the deal also involves financing to the partner, which could speed up the development process. In the latest company-sponsored report from Analysguiden, they had a value of SEK 0.2 per share probability adjusted assigned to the malaria pipeline based on a 10% probability of success. Further details about the commercialization could change this value expectations. 

ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system.

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis, 08:00 (updated 08:56) AM, 17.10.2024.